老年精神病学专家Amanda Grant Smith分享了她对阿尔茨海默病和痴呆患者的治疗经验，探讨了如何识别、定义和诊断痴呆症，以及ApoE基因型的重要性。她还讨论了当前临床试验的现状，一种针对淀粉样β的单克隆抗体药物的前景，以及如何定义“健康衰老”。

🌟 Amanda Grant Smith如何培养对老年精神病学热情，支持痴呆症患者。[详细]她讲述了自己的职业发展历程，以及她如何通过专业实践来改善痴呆症患者的生活质量。

💡 痴呆症和阿尔茨海默病的定义与诊断。[详细]她详细解释了痴呆症的诊断过程，包括目前诊断方法的挑战和最新进展。

🔬 ApoE基因型的重要性及阿尔茨海默病与路易体痴呆的鉴别。[详细]她探讨了ApoE基因型在痴呆症中的作用，以及如何区分阿尔茨海默病和路易体痴呆。

📉 过去20年阿尔茨海默病预防、护理和药物治疗的演变。[详细]她回顾了阿尔茨海默病治疗领域的重大变化，包括药物治疗和护理实践的进步。

🧪 单克隆抗体治疗阿尔茨海默病的希望。[详细]她介绍了一种有前景的单克隆抗体药物，这种药物可能成为改变阿尔茨海默病治疗方式的疾病修饰药物。

Amanda Grant Smith is a geriatric psychiatrist with decades of experience treating patients with dementia and Alzheimer's disease. In this episode, Amanda shares how she developed a passion for geriatric psychiatry as a means to support dementia patients. She explains how to recognize, define, and diagnose dementia—a process that still remains somewhat elusive. They also talk about the significance of ApoE genotype and compare the various forms of dementia including differentiating between Alzheimer’s disease and Lewy body dementia. They discuss the current landscape of clinical trials, the drug pipeline, and talk about a very promising monoclonal antibody directed at amyloid beta that has the potential to be a disease-modifying drug. They conclude with a discussion about how to define “healthy aging” and reflect on how understanding dementia can shape one’s life philosophy.

 

We discuss:

How Amanda developed a passion for geriatric psychiatry [3:15]; Defining and diagnosing dementia and Alzheimer’s disease [13:30]; Medical tests for dementia and their relationship to clinical symptoms [22:45]; The pathology of dementia, and the role of the tau and beta-amyloid protein in Alzheimer’s disease [33:15]; The significance of ApoE genotype, and differentiating Alzheimer’s disease from Lewy body dementia [43:15]; The evolution of Alzheimer’s disease prevention, care, and medications over the last 20 years [52:45]; Psychiatric support for dementia patients (and caregivers) with depression and anxiety [1:02:45]; Drug pipeline, clinical trials, and major challenges to overcome [1:13:45]; Redefining Alzheimer’s disease and designing effective trials [1:23:00]; The promise of monoclonal antibody treatments for Alzheimer’s disease [1:34:15]; How we should measure outcomes in dementia trials and define “healthy aging” [1:42:30]; How understanding dementia can reshape our life philosophy [1:53:45]; and More.

Learn more: https://peterattiamd.com/ Show notes page for this episode: https://peterattiamd.com/AmandaSmith Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on Facebook | Twitter | Instagram.